MADRID (Reuters) – Spain’s Grifols (GRLS.MC) has agreed to buy Talecris Biotherapeutics (TLCR.O), which produces plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products. Grifols said on Monday it expected about $230 million annual synergies from the deal, which has been unanimously approved by both companies’ boards [...]

NEW YORK (Reuters) – Talecris Biotherapeutics Holdings Corp (TLCR.O) shares rose 13.3 percent in their trading debut following the Cerberus-backed company’s initial public offering, the largest by a biopharmaceuticals company in three years. Talecris, which produces plasma-based protein therapies, raised $950 million in its IPO on Wednesday. The shares stood at $21.52 in midday Nasdaq [...]

NEW YORK (Reuters) – Talecris Biotherapeutics Holdings Corp priced shares in its initial public offering for $19 each, within the expected range, but increased the size of the share issue in the largest IPO by a biopharmaceuticals firm in three years. Talecris, which produces plasma-based protein therapies, sold 50 million shares, 11.8 percent more than [...]

Earlier today I took a left out of the home office, and sat down next to the washer/dryer for a Reuters video segment on PE-backed IPOs. Topics include Talecris Biotherapeutics (the hit Cerberus has been thirsting for?), Dollarama/Dollar General (countercyclical indicators?) and Peak Sports (the Sequoia Capital IPO no one in the Valley is talking about):

Talecris Biotherapeutics Holding Corp., a Research Triangle Park, N.C.-based developer of plasma-derived protein therapies, last month filed a pair of amendments to its original IPO filing. Neither amendment disclosed the number of shares to be offered or a price range, but did indicate that the company still plans to go public. Talecris had originally filed [...]

WASHINGTON (Reuters) – Australian blood products group CSL Ltd (CSL.AX) (CSL.AX) and smaller U.S. rival Talecris Biotherapeutics Holdings Corp have terminated their $3.1 billion merger agreement under pressure from U.S. antitrust regulators, the companies said on Monday. CSL, which also makes vaccines, said in August that it would buy Talecris, looking to boost its presence [...]

What: CLS Ltd. (AX: CSL) agreed to buy Talecris Biotherapeutics Holdings Corp. for US$3.1 billion. Talecris is a U.S. operator of 56 blood plasma collection centers and two manufacturing facilities, and was acquired by Cerberus Capital Management and Ampersand Ventures two years ago from Bayer AG. CSL is partially financing the deal via a $1.55 [...]